- Using Tesla Math, GM’s Buick Unit Should Be Worth $1.1 Trillion
- No, Tesla Does Not Outsell the Mercedes S-Class in the U.S. or Globally
- The 10 Most 'Socialist' States in America
- TheStreet Seeks Retraction From Washington Post on Steven Pearlstein Column
- Will Bendgate Have Any Long-Term Effect on Apple's iPhone 6 Plus Legacy?
Ebola lands in Texas, so expect some crazy volatility Wednesday in biotech and drug stocks.
Martin is super smart and will be a great asset somewhere, but he is not a CEO. I wish him the best.
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.
Clovis Oncology shares are higher Monday because AstraZeneca, its direct competitor to develop a new, genetically targeted lung cancer drug, slipped this weekend.
Adcetris delayed disease progression in Hodgkin lymphoma patients following a stem cell transplant.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.
Results from a phase III study of Alcobra's MDX in adult ADHD are expected within the next week.
Baxter has a hunger for cancer drugs with hair.